Document is current
Any future updates will be listed below
-
Authors
Askeland, Frida Bugge https://orcid.org/0000-0002-8512-8577
Bugge, Vilhelm Hauge https://orcid.org/0009-0000-7120-5706
Rasmussen, Anne-Marie
Lysén, Anna
Haukås, Einar
Moksnes, Magnus
Eilertsen, Anette L. https://orcid.org/0009-0006-2323-2578
Tsykunova, Galina
Eiken, Birgitte Dahl
Leknes, Nils Morten https://orcid.org/0009-0006-1011-138X
Rolke, Jürgen
Stavseth, Vidar
Samstad, Eivind https://orcid.org/0000-0002-0366-3796
Hallstensen, Randi Fykse
Szatkowski, Damian https://orcid.org/0009-0008-9212-9595
Hansen, Ariane Aasbø
Nilsen, Anita Smith
Slørdahl, Tobias S. https://orcid.org/0000-0001-7488-4863
Abdollahi, Pegah https://orcid.org/0000-0002-9331-7992
Schjesvold, Fredrik https://orcid.org/0000-0003-1096-0569
-
Funding
Funding for this research was provided by:
The Norwegian Government (KLINBEFORSK). The Norwegian Cancer Society. MATRIX. J&J Innovative Medicine. BMS/Celgene. the Binding Site. GSK.
- License Information
-
More Information
Article History
Received: 19 August 2025
Revised: 4 October 2025
Accepted: 24 October 2025
First Online: 22 December 2025
Competing interests
: FBA has received honoraria or payments from J&J and Sanofi, and has participated in advisory boards for J&J and Sanofi. EH has received honoraria or payments from J&J and has participated in advisory boards for Sanofi. MM has received honoraria or payments from J&J and AbbVie, and has participated in advisory boards for Sanofi, AbbVie, Shire, and Lilly. ALE has received honoraria or payments from J&J, Bayer, Pfizer, and Incyte; and participated in advisory boards for Sanofi, J&J, Pfizer, and GSK. GT has received honoraria or payments from J&J, Sanofi, SOBI, and Grifols, and has participated in advisory boards for J&J, Sanofi, SOBI, and Grifols. VS has received honoraria or payments from J&J. TSS has received honoraria for lectures and educational material from Takeda, Celgene, Amgen, J&J, AbbVie, and Pfizer; has received consulting fees from BMS, GSK, Sanofi, Pfizer, and Menarini Group; and has participated in advisory boards for Amgen, Celgene, GSK, J&J, Sanofi, and BMS. FS has received grants from Targovax; has received consulting fees from Caedo Therapeutics; has received honoraria/payment from Amgen, BMS, Takeda, Sanofi, Menarini, AbbVie, J&J, Oncopeptides, and GSK; has participated on advisory boards or data safety monitoring for GSK, Takeda, BMS, J&J, Oncopeptides, Regeneron, Sanofi, XNK Therapeutics, Galapagos, and Pfizer; and is the president of the Nordic Myeloma Study Group (academic group). All other authors declare no competing interests.
